Xiaoyan Lin - Concepedia

Author

Xiaoyan Lin

Also Known As

Huimin Xiao, Lin, Xiaoyan, X Lin, X. Lin, X.Y. Lin, Xianjin Lin, Xiao-Tong Lin, Xiao-Yan Lin, Xiao-tong Lin, Xiao-yan LIN

152

Publications

5.9K

Citations

H-Index

Concepts

All Affiliations

Fujian Medical University Union Hospital Peking University Hunan Cancer Hospital Peking University Cancer Hospital

About

Xiaoyan Lin is an author at Fujian Medical University specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	2.9K
2	Health Sciences	2	2	507
3	Education	1	1	12
4	Social Sciences	1	1	12
5	Biochemistry	1	1	56

Xiaoyan Lin

Publications

Citations

H-Index

Page 1

	Year	Citations
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction Jin Li, Shukui Qin, Jianming Xu, Journal of Clinical Oncology	2016	976
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial Shukui Qin, Zhenggang Ren, Zhiqiang Meng, The Lancet Oncology HepatologyMedicinePathologyLiver CancerCancer Treatment	2020	625
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study Shukui Qin, Stephen L. Chan, Shanzhi Gu, The Lancet First-line TherapyHepatologyInternational Phase 3MedicinePathology	2023	590
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial Caicun Zhou, Gongyan Chen, Yunchao Huang, The Lancet Respiratory Medicine OncologyClinical TrialsChemotherapy-naive PatientsImmune Checkpoint InhibitorPharmacotherapy	2020	488
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Nature Medicine OncologyMetronomic TherapyNasopharyngeal CancerFirst-line TreatmentCancer Treatment	2021	387
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02) Feng‐Hua Wang, Xiaoli Wei, Jifeng Feng, Journal of Clinical Oncology	2021	336
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma Hai‐Qiang Mai, Qiuyan Chen, Dongping Chen, JAMA	2023	196
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial Xiangyu Gao, Nong Xu, Ziyu Li, The Lancet Oncology OncologyMedicineAdvanced Solid TumoursImmune Checkpoint InhibitorAnti-cancer Agent	2023	171
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial Yun Fan, Jun Zhao, Qiming Wang, Journal of Thoracic Oncology Camrelizumab Plus ApatinibMedicinePharmacologyClinical TrialsTherapeutic Efficacy	2020	137
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial Feng Wang, Shukui Qin, Xinchen Sun, Journal of Hematology & Oncology Multicenter Phase 2ImmunologyPathologyImmunotherapeuticsDermatology	2020	132

Page 1